Vertex Pharmaceuticals Aktie
| 401,23USD | 4,08USD | 1,03% |
WKN: 882807 / ISIN: US92532F1003
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,75 |
| Capital Research & Management Co. (World Investors) | 10,41 |
| Capital Research & Management Co. (World Investors) | 10,06 |
| The Vanguard Group, Inc. | 8,65 |
| Vanguard Group, Inc. (Subfiler) | 8,54 |
| State Street Corp. | 4,59 |
| Capital Research & Management Co. (Global Investors) | 3,50 |
| BlackRock Fund Advisors | 3,37 |
| Vanguard Total Stock Market ETF | 3,17 |
| American Funds Growth Fund of America | 3,15 |
| Fidelity Management & Research Co. LLC | 3,02 |
| AllianceBernstein LP | 2,86 |
| Vanguard 500 Index Fund | 2,66 |
| Geode Capital Management LLC | 2,30 |
| BlackRock Institutional Trust Co. NA | 2,23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3 000 | 3 400 | 3 900 | 4 800 | 5 400 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,38 | 1,83 | 1,95 | 1,82 | 1,82 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4 823 | 8 133 | 9 561 | 13 235 | 14 144 |
| Summe Anlagevermögen | 3 496 | 3 618 | 3 872 | 4 916 | 8 942 |
| Summe Aktiva | 8 318 | 11 752 | 13 433 | 18 151 | 23 086 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 2 233 | 3 065 | 3 333 | 4 238 | 5 506 |
| Summe Eigenkapital | 6 085 | 8 687 | 10 100 | 13 913 | 17 580 |
| Summe Passiva | 8 318 | 11 752 | 13 433 | 18 151 | 23 086 |
Adresse
| 50 Northern Avenue, 02210 Boston | |
| Telefon | +1 (617) 341-6100 |
| Internet | http://www.vrtx.com |
Management
|
Alan M. Garber
Independent Director |
|
Amit K. Sachdev
Chief Patient Officer & Executive Vice President |
|
Bruce I. Sachs
Lead Independent Director |
|
Carmen Bozic
Chief Medical Officer & EVP-Medical Affairs |
|
Catherine Rutten
Vice President-International & Government Affairs |
|
Charles F. Wagner
Chief Financial Officer & Executive Vice President |
|
David Matthew Altshuler
Chief Scientific Officer & EVP-Global Research |
|
Diana L. McKenzie
Independent Director |
|
Edward Morrow Atkinson
Chief Technical Operations Officer & Executive VP |
|
Jeffrey M. Leiden
Executive Chairman |
|
Jennifer Schneider
Independent Director |
|
Jonathan Prim Biller
Chief Legal Officer & Executive Vice President |
|
Joy Liu
Secretary, Senior Vice President & General Counsel |
|
Kristen C. Ambrose
Chief Accounting Officer & Senior Vice President |
|
Lloyd A. Carney
Independent Director |
|
Ludovic Fenaux
Senior VP-International Commercial Operations |
|
Mark Bunnage
Senior Vice President & Head-Research |
|
Michel Lagarde
Independent Director |
|
Mike Tirozzi
Senior VP, Chief Information & Data Officer |
|
Nancy A. Thornberry
Independent Director |
|
Nia Tatsis
Chief Regulatory & Quality Officer, Executive VP |
|
Reshma Kewalramani
President, Chief Executive Officer & Director |
|
Sangeeta N. Bhatia
Independent Director |
|
Sean Daughtry
Senior Director-Analytical Sciences & Technology |
|
Stephanie Franklin
Chief Human Resources Officer & Senior VP |
|
Stuart A. Arbuckle
Chief Operating Officer & Executive Vice President |
|
Suketu P. Upadhyay
Independent Director |
|
Susie Lisa
Senior Vice President-Investor Relations |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
